Pancreatic Cancer Research

ResearcherNagoya City UniversityNo recent work listed

Hiromitsu Takeyama

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110693648. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
10
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper

Papers 4

  1. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. Last author DOI 10.1186/s12885-016-2340-z↗
  2. Zerumbone inhibits angiogenesis by blocking NF-κB activity in pancreatic cancer. Last author DOI 10.1097/mpa.0000000000000039↗
  3. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. Co-author DOI 10.1016/j.bbamcr.2013.08.006↗
  4. Cytokine network: new targeted therapy for pancreatic cancer. First author DOI 10.2174/13816128112092416↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoichi Matsuo · 4 shared papers, 2012–2016 · strength 0.19
  2. Hiroki Takahashi · 3 shared papers, 2013–2016 · strength 0.14
  3. Tomoya Shamoto · 2 shared papers, 2014–2016 · strength 0.10
  4. Mamoru Morimoto · 1 shared paper, 2016 · strength 0.06
  5. Kenta Saito · 1 shared paper, 2016 · strength 0.06
  6. Sushovan Guha · 1 shared paper, 2012 · strength 0.05
  7. Howard A. Reber · 1 shared paper, 2013 · strength 0.04
  8. Hung Pham · 1 shared paper, 2013 · strength 0.04
  9. Guido Eibl · 1 shared paper, 2013 · strength 0.04
  10. Oscar Joe Hines · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.